The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | Unmet treatment needs in subgroups of patients with multiple myeloma
Meral Beksac, MD, PhD, Ankara University, Ankara, Turkey, discusses unmet treatment needs in multiple myeloma (MM). She highlights several key patient subgroups: those with extramedullary disease, who showed inferior response rates in the EMN19 trial (NCT04166565); patients with renal impairment; patients with bone lesions; and those facing emerging infections following CAR-T treatment. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: BMS, Takeda, Amgen; Advisory Board: Pfizer, Menarini, Janssen; Speakers Bureau: Janssen.
